Cost-benefit analysis can be used to quantify the value of clinical pharmacy services. Providing Effective Therapy and Minimum cost, Quantify costs of care, Quantify outcomes, Assess whether and by how much average costs and outcomes differ among treatment groups, Compare magnitude of difference in costs and outcomes and evaluate "value for costs" by reporting a cost-effectiveness ratio, net monetary benefit, or probability that ratio is acceptable -Potential hypothesis: Cost per quality-adjusted life year saved significantly less than Rs.75,000, To Perform sensitivity analysis. For providing good effective therapy with less adverse drug reaction at affordable price,
INTRODUCTION
A Pharmacoeconomics study evaluates the cost and effects (expressed in terms of monetary value, effectiveness, efficacy or enhanced quality of life) of a pharmaceutical product. [1] It identifies, measures, and compares the costs and consequences of drug therapy to healthcare systems and society. Pharmacoeconomics research in the managed care consolidation to diversification. Health Economics, as a branch of economics is itself relatively young [3] . Basically the pharmacoeconomics is needful in following manner;
• In Industry: Deciding among specific research and development alternatives.
• In Government: Determining program benefits and prices paid.
• In Private Sector: Designing insurance benefit coverage.
The direct medical costs contain the hospitalization, outpatient visits (to primary care providers and to specialists), procedures and tests (blood analysis, ultrasound scans, surgical interventions), medical devices, home care, nursing care and medications. The direct nonmedical costs comprise the transportations, nonmedical services (home helper, meals on wheels, social assistance), devices and investments or the informal care. The indirect costs are mostly mean the sick leave or absences, reduced productivity at work, early retirement due to illness and the premature death [13] .
Cost-minimization analysis (CMA)
Cost-minimization or cost-identification is an analytical process used in pharmacoeconomics to examine the cost of drug treatment when the clinical effectiveness of the alternative therapies is identical.
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Cost-effectiveness (CEA) and cost-utility analysis (CUA)
The professional literature distinguishes two analysis methods, where the costs and the utilities or benefits -opposite to the cost-benefit analysis -measured in different units: these are the cost-effectiveness (CEA) and the cost-utility analysis (CUA). As long as at the former method the outcomes are measured in some clinical characteristics, at the CUA the outcomes are expressed in special units, in quality adjusted life years (QALY), while the costs are calculated in monetary units. According to Wonderling [28] cost-effectiveness analysis (CEA) is an economical or management tool for evaluating which therapy are the most costeffective, so how to achieve greater effect next to unchanged expenditures or lower costs next to unchanged effects. The expansion in use of economic evaluation by health agencies has mirrored the growing recognition of the usefulness of health-related quality of life (HrQoL) as an important indicator of outcome of disease treatment among clinicians and patients [21] . Like the CMA in micro level the application of CEA could show in the following example: there are four therapies, which treated the same type of disease (providing the comparability of their costs) and the effects are measured in quality of life generally.
Cost-benefit analysis (CBA)
According to David [71] the cost-benefit analysis is a technique that is used to determine options that provide the best approach for the adoption and practice in terms of benefits in labour, time and cost savings. Like the CEA and CUA, the CBA also compare the costs and the benefits but those are expressed in the same monetary units -as the health project forming part of government policy may take several years, so in the CBA the time value of money take part too. The common basis can provide the comparability: this is the net present value [32] . Cost-benefit analysis, which used by institutions those operate the total health system, can influence a health policy of government so this analysis used rather in macro level. Therefore, the applied discount rate we should assume that the examined health projects are occurred in the same interest rate environment and because of the dependence of method from the net present value -so from the time value of money -the duration of projects should also be identical.
Consequences [38] [39] [40] [41] [42] According to our current knowledge there are three different analysis methods used in the health economy: the cost-minimization, the cost-effectivenessinside of this the cost-utility -and the cost-benefit analysis. Application of all three methods has difficulty because of the effects or benefits of therapies or health projects are estimated hardly. Therefore, it can determine that these methods apply effectively when the compared therapies treated the same type of diseases, the main health, financial and other economic factors those can impact to the valuation consider equivalent, so these are realized under the same macroeconomic conditions, finally all information should be available for the estimation. However experts formulated several critics against the, in micro level the cost-utility analysis is advisable to apply, since in macro level the use of cost-benefit analysis can contribute mostly to the better operation of health supply system.
MATERIAL
Selection of a Survey Frame:
The survey frame provides the means of identifying and contacting the units of the survey population. The frame is in the form of a list, for example.
• Number of TB research Centre Market Survey [53] • Retail outlet in TB center and Outside the Tb center 
Steps of a Survey
It may appear that conducting a survey is a simple procedure of asking questions and then compiling the answers to produce statistics. However, a survey must be carried out step by step, following precise procedures and formulas, if the results are to yield accurate and meaningful information. 
Formulation of the Statement of Objectives
One of the most important tasks in a survey is to formulate the Statement of Objectives. This establishes not only the survey's broad information needs, but the operational definitions to be used, the specific topics to be addressed and the analysis plan.
Data Capture and Coding
After the data are collected, they are coded and, if a computer-assisted collection method was not used, captured. Coding is the process of assigning a numerical value to responses to facilitate data capture and processing in general.
Estimation
Once the data have been collected, captured, coded, the next step is estimation. Estimation is the means by which the statistical agency obtains values for the population of interest so that it can draw conclusions about that population based on information gathered from only a sample of the population. An estimate may be a total, mean, ratio, percentage, etc.
Data Analysis
Data analysis involves summarizing the data and interpreting their meaning in a way that provides clear answers to questions that initiated the survey. Data analysis should relate the survey results to the questions and issues identified by the Statement of Objectives. It is one of the most crucial steps of a survey since the quality of the analysis can substantially affect the usefulness of the whole survey.
Documentation
Documentation provides a record of the survey and should encompass every survey step and every survey phase. It may record different aspects of the survey and be aimed at different groups, such as management, technical staff, designers of other surveys and users. For example, a report on data quality provides users a context for informed use of the data. A survey report that includes not only what decisions were made, but also why they were made provides management and technical staff with useful information for future development and implementation of similar surveys. During implementation, documentation of procedures for staff helps to ensure effective implementation. Market survey: Retail outlet in TB center and Outside the TB center, Reliable brands as well as low cost brands, Questions to retailer, collecting retailer data
RESULT AND DISCUSSION
CONCLUSION
As we know that TB is most infectious disease cause by Mycobacterium Tuberculosis it mainly affects the respiratory tract. As per clinical and market survey we found that Rifampicin is most trusted anti-TB drug and R-cin450 was found to be most prescribed and selling brand in the market. Rifampicin occupies 69% in the market. Ethambutol occupies 20% in the market. Other anti-TB drug occupy 11% in the market. Rifampicin has less ADR and it is most prescribed drug as compared to Ethambutol. We can minimize the cost by prescribing generic drug. Rifampicin has less ADR (headache, stomach upset, nausea, vomiting, dizziness) as compare to Ethambutol ADR (heart burning, loss of appitite, menstrual changes, urine discolour). We can change reduce the cost of anti-TB therapy by using generic drugs at the place of prescribed brand. Because generic drug are approximately 60% less in cost than other branded drugs. 
